MiMedx Group Inc.

MDXG

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Deerfield Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Deerfield ManagementNEWFeb 17, 2026

Shares: 160,419Value: $1.1M

# Signal Note: Deerfield Initiates MDXG Position Deerfield Management's $1.1M entry into MiMedx suggests confidence in the company's regenerative medicine portfolio, particularly its placental tissue-derived products (EpiFix, AmnioFix) used in wound care and orthopedic applications. The timing may reflect conviction in upcoming clinical data, reimbursement developments, or potential M&A activity in the allograft biologics space, which has seen recent consolidation. Monitor Q3/Q4 2024 for material announcements on expanded Medicare coverage, clinical outcomes, or strategic partnerships that would validate this thesis.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

RDNT1 fund VTR1 fund PHVS1 fund PMVP1 fund ALHC1 fund ATRC1 fund BCRX1 fund NBIX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: